Baseline demographics and clinical characteristics of the study population
| Characteristics . | Subjects (n = 44) . |
|---|---|
| Median age (range), y | 49 (20-83) |
| Sex, n (%) | |
| Female | 25 (56.8) |
| Male | 19 (43.2) |
| Secondary ITP,∗ n (%) | 14 (31.8) |
| Evans syndrome | 8 (18.2) |
| Systemic lupus erythematosus | 3 (6.8) |
| Inflammatory bowel disease | 2 (4.5) |
| Rheumatoid arthritis | 1 (2.3) |
| Antiphospholipid syndrome | 1 (2.3) |
| Common variable immunodeficiency | 1 (2.3) |
| Inflammatory disorder NOS | 1 (2.3) |
| Median duration of ITP (range), y | 8.2 (0.3 – 32.9) |
| Median age at diagnosis of ITP (range), y | 40 (2-77) |
| Mean baseline platelet count (range), x 109/L | 161 (16-646) |
| Median no. of previous ITP therapies (range) | 4 (0-13) |
| History of splenectomy, n (%) | 14 (31.8) |
| Prior rituximab, n (%) | 21 (47.7) |
| Most common current therapy, n (%) | |
| Thrombopoietin receptor agonists | 23 (52.3) |
| Not on therapy | 15 (34.1) |
| Corticosteroids | 11 (25.0) |
| Mycophenolate mofetil | 9 (20.5) |
| Lymphadenopathy or splenomegaly, n (%) | 9 (20.5) |
| Personal history of autoimmunity, n (%) | 20 (45.5) |
| Family history of autoimmunity | |
| In a first-degree relative, n (%) | 19 (43.2) |
| In any relative, n (%) | 25 (56.8) |
| Characteristics . | Subjects (n = 44) . |
|---|---|
| Median age (range), y | 49 (20-83) |
| Sex, n (%) | |
| Female | 25 (56.8) |
| Male | 19 (43.2) |
| Secondary ITP,∗ n (%) | 14 (31.8) |
| Evans syndrome | 8 (18.2) |
| Systemic lupus erythematosus | 3 (6.8) |
| Inflammatory bowel disease | 2 (4.5) |
| Rheumatoid arthritis | 1 (2.3) |
| Antiphospholipid syndrome | 1 (2.3) |
| Common variable immunodeficiency | 1 (2.3) |
| Inflammatory disorder NOS | 1 (2.3) |
| Median duration of ITP (range), y | 8.2 (0.3 – 32.9) |
| Median age at diagnosis of ITP (range), y | 40 (2-77) |
| Mean baseline platelet count (range), x 109/L | 161 (16-646) |
| Median no. of previous ITP therapies (range) | 4 (0-13) |
| History of splenectomy, n (%) | 14 (31.8) |
| Prior rituximab, n (%) | 21 (47.7) |
| Most common current therapy, n (%) | |
| Thrombopoietin receptor agonists | 23 (52.3) |
| Not on therapy | 15 (34.1) |
| Corticosteroids | 11 (25.0) |
| Mycophenolate mofetil | 9 (20.5) |
| Lymphadenopathy or splenomegaly, n (%) | 9 (20.5) |
| Personal history of autoimmunity, n (%) | 20 (45.5) |
| Family history of autoimmunity | |
| In a first-degree relative, n (%) | 19 (43.2) |
| In any relative, n (%) | 25 (56.8) |
NOS, not otherwise specified.
One patient was concurrently diagnosed with Evans syndrome, systemic lupus erythematosus, and antiphospholipid syndrome; 1 was diagnosed with primary sclerosing cholangitis, ulcerative colitis, and rheumatoid arthritis.